Drug Trial Radar · NCT00338650
Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)
Last checked: Nov 20, 2026Latest source record: Nov 29, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,000
Actual
Start
Jun 2006
Primary completion
Not stated
Study completion May 2007
Sponsor
- Lead sponsor
- AbbottIndustry
- Sponsor type
- Industry
- First posted
- Jun 20, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to make adalimumab available to patients suffering from moderately to severely active Crohn's Disease who have failed to respond to, lost response to, or are intolerant to infliximab, and to evaluate safety
Conditions
- Crohn's Disease
Interventions
adalimumabDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- AEs, laboratory data, physical examinations and vital signs
Locations
97 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Jonesboro, Arkansas
Site not named
Little Rock, Arkansas
Site not named
Roseville, California
Site not named
San Francisco, California
Site not named
Englewood, Colorado
Site not named
Wheat Ridge, Colorado
Site not named
Bridgeport, Connecticut
Site not named
Hamden, Connecticut
Site not named
Clearwater, Florida
Site not named
Gainesville, Florida
Site not named
Gainesville, Florida
Site not named
Hollywood, Florida
Site not named
Jacksonville, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
North Miami Beach, Florida
Site not named
Winter Park, Florida
Site not named
Atlanta, Georgia
Site not named
Atlanta, Georgia
Site not named
Atlanta, Georgia
Site not named
Conyers, Georgia
Site not named
Marietta, Georgia
Site not named
Savannah, Georgia
Site not named
Arlington Heights, Illinois
Site not named
Moline, Illinois
Site not named
Rockford, Illinois
Site not named
Columbus, Indiana
Site not named
Indianapolis, Indiana
Site not named
Indianapolis, Indiana
Site not named
Clive, Iowa
Site not named
Davenport, Iowa
Site not named
Overland Park, Kansas
Site not named
Topeka, Kansas
Site not named
Lexington, Kentucky
Site not named
Annapolis, Maryland
Site not named
Chevy Chase, Maryland
Site not named
Lutherville, Maryland
Site not named
Silver Spring, Maryland
Site not named
Boston, Massachusetts
Showing 40 of 97 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.